United Statesprometheusbiosciences.com
Prometheus Biosciences, Inc. is a biotechnology company focused on precision therapies and companion diagnostics for immune-mediated diseases, with a primary emphasis on inflammatory bowel disease (ulcerative colitis and Crohn’s disease). Headquartered in San Diego, the company became part of Merck & Co., Inc. in 2023.
Prometheus applies a data-driven, multi-omics approach to identify patient subpopulations and develop targeted biologics. Its pipeline includes monoclonal antibody programs directed at pathways implicated in intestinal inflammation, notably an anti-TL1A candidate in advanced clinical development for IBD, supported by biomarker-based patient selection. The company’s activities span discovery through clinical trials, integrating translational research and companion diagnostic development to link disease biology with therapeutic response.
None yet. When a new project in the record names Prometheus BioSciences as owner, partner or investor, it shows here.
Merck ends co-development with Falk, assumes full responsibility for MK-8690, pays $150M upfront, and records a pre-tax charge in Q4 results.
